Logo image of SGMO

SANGAMO THERAPEUTICS INC (SGMO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SGMO - US8006771062 - Common Stock

0.445 USD
+0.02 (+3.49%)
Last: 12/24/2025, 8:00:56 PM
0.4322 USD
-0.01 (-2.88%)
After Hours: 12/24/2025, 8:00:56 PM
Fundamental Rating

2

Overall SGMO gets a fundamental rating of 2 out of 10. We evaluated SGMO against 530 industry peers in the Biotechnology industry. While SGMO seems to be doing ok healthwise, there are quite some concerns on its profitability. SGMO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SGMO had negative earnings in the past year.
In the past year SGMO has reported a negative cash flow from operations.
SGMO had negative earnings in each of the past 5 years.
In the past 5 years SGMO reported 4 times negative operating cash flow.
SGMO Yearly Net Income VS EBIT VS OCF VS FCFSGMO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

SGMO has a worse Return On Assets (-122.86%) than 80.57% of its industry peers.
SGMO has a Return On Equity of -1744.50%. This is amonst the worse of the industry: SGMO underperforms 82.64% of its industry peers.
Industry RankSector Rank
ROA -122.86%
ROE -1744.5%
ROIC N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
SGMO Yearly ROA, ROE, ROICSGMO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

SGMO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMO Yearly Profit, Operating, Gross MarginsSGMO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

SGMO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SGMO has been increased compared to 1 year ago.
Compared to 5 years ago, SGMO has more shares outstanding
SGMO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGMO Yearly Shares OutstandingSGMO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SGMO Yearly Total Debt VS Total AssetsSGMO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -27.79, we must say that SGMO is in the distress zone and has some risk of bankruptcy.
SGMO's Altman-Z score of -27.79 is on the low side compared to the rest of the industry. SGMO is outperformed by 87.92% of its industry peers.
There is no outstanding debt for SGMO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.79
ROIC/WACCN/A
WACC8.82%
SGMO Yearly LT Debt VS Equity VS FCFSGMO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 0.88 indicates that SGMO may have some problems paying its short term obligations.
SGMO has a Current ratio of 0.88. This is amonst the worse of the industry: SGMO underperforms 89.06% of its industry peers.
A Quick Ratio of 0.88 indicates that SGMO may have some problems paying its short term obligations.
With a Quick ratio value of 0.88, SGMO is not doing good in the industry: 88.68% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.88
SGMO Yearly Current Assets VS Current LiabilitesSGMO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

SGMO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.33%, which is quite impressive.
Looking at the last year, SGMO shows a very negative growth in Revenue. The Revenue has decreased by -37.70% in the last year.
The Revenue for SGMO have been decreasing by -10.81% on average. This is quite bad
EPS 1Y (TTM)41.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-375%
Revenue 1Y (TTM)-37.7%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%-98.82%

3.2 Future

The Earnings Per Share is expected to grow by 22.96% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 38.32% on average over the next years. This is a very strong growth
EPS Next Y34.33%
EPS Next 2Y17.48%
EPS Next 3Y16.03%
EPS Next 5Y22.96%
Revenue Next Year-5.05%
Revenue Next 2Y-10.87%
Revenue Next 3Y29.21%
Revenue Next 5Y38.32%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SGMO Yearly Revenue VS EstimatesSGMO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
SGMO Yearly EPS VS EstimatesSGMO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGMO. In the last year negative earnings were reported.
Also next year SGMO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMO Price Earnings VS Forward Price EarningsSGMO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMO Per share dataSGMO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4

4.3 Compensation for Growth

SGMO's earnings are expected to grow with 16.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.48%
EPS Next 3Y16.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGMO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SANGAMO THERAPEUTICS INC

NASDAQ:SGMO (12/24/2025, 8:00:56 PM)

After market: 0.4322 -0.01 (-2.88%)

0.445

+0.02 (+3.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-16 2026-03-16/amc
Inst Owners18.77%
Inst Owner Change22.14%
Ins Owners0.86%
Ins Owner Change-5.69%
Market Cap149.74M
Revenue(TTM)32.88M
Net Income(TTM)-108.91M
Analysts78.33
Price TargetN/A
Short Float %5.28%
Short Ratio2.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31749.3%
Min EPS beat(2)-63537.1%
Max EPS beat(2)38.49%
EPS beat(4)1
Avg EPS beat(4)-15880.5%
Min EPS beat(4)-63537.1%
Max EPS beat(4)38.49%
EPS beat(8)2
Avg EPS beat(8)-7919.96%
EPS beat(12)4
Avg EPS beat(12)-5281.72%
EPS beat(16)8
Avg EPS beat(16)-3957.71%
Revenue beat(2)0
Avg Revenue beat(2)-70.85%
Min Revenue beat(2)-98.34%
Max Revenue beat(2)-43.35%
Revenue beat(4)0
Avg Revenue beat(4)-50.56%
Min Revenue beat(4)-98.34%
Max Revenue beat(4)-14.91%
Revenue beat(8)1
Avg Revenue beat(8)-37.03%
Revenue beat(12)2
Avg Revenue beat(12)15.02%
Revenue beat(16)5
Avg Revenue beat(16)12.37%
PT rev (1m)-20.73%
PT rev (3m)-20.73%
EPS NQ rev (1m)-12.52%
EPS NQ rev (3m)34.35%
EPS NY rev (1m)-14.98%
EPS NY rev (3m)-13.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)54.02%
Revenue NY rev (1m)-21.1%
Revenue NY rev (3m)-21.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.55
P/FCF N/A
P/OCF N/A
P/B 23.98
P/tB 23.98
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.1
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.86%
ROE -1744.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.5%
ROA(5y)-64.82%
ROE(3y)-268.79%
ROE(5y)-175.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.66%
Cap/Sales 0.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.88
Altman-Z -27.79
F-Score4
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)104.2%
Cap/Depr(5y)163.67%
Cap/Sales(3y)10.21%
Cap/Sales(5y)12.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-375%
EPS Next Y34.33%
EPS Next 2Y17.48%
EPS Next 3Y16.03%
EPS Next 5Y22.96%
Revenue 1Y (TTM)-37.7%
Revenue growth 3Y-19.48%
Revenue growth 5Y-10.81%
Sales Q2Q%-98.82%
Revenue Next Year-5.05%
Revenue Next 2Y-10.87%
Revenue Next 3Y29.21%
Revenue Next 5Y38.32%
EBIT growth 1Y35.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year28.95%
EBIT Next 3Y-31.75%
EBIT Next 5Y34.36%
FCF growth 1Y70.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.07%
OCF growth 3YN/A
OCF growth 5YN/A

SANGAMO THERAPEUTICS INC / SGMO FAQ

What is the ChartMill fundamental rating of SANGAMO THERAPEUTICS INC (SGMO) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SGMO.


Can you provide the valuation status for SANGAMO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to SANGAMO THERAPEUTICS INC (SGMO). This can be considered as Overvalued.


Can you provide the profitability details for SANGAMO THERAPEUTICS INC?

SANGAMO THERAPEUTICS INC (SGMO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for SGMO stock?

The Earnings per Share (EPS) of SANGAMO THERAPEUTICS INC (SGMO) is expected to grow by 34.33% in the next year.